Reata Pharmaceuticals, Inc. is looking ahead to a wide-open commercial opportunity following the US Food and Drug Administration approval of Skyclarys (omaveloxolone) as the first approved drug for the rare neurodegenerative disease Friedreich’s ataxia (FA).
Reata Lays Commercial Path For Skyclarys With First-Ever Friedreich’s Ataxia Nod
The company forecasts an addressable US patient market that comprises 90% of the total Friedreich’s population of 5,000 based on a broad label covering patients aged 16 and older.
More from New Products
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.